Key Highlights:
- NeuroOne to Present at MedInvest’s Flagship Conference: Showcases breakthroughs in brain stimulation, ablation, and diagnostic technologies.
- Strategic Focus on AI, Chronic Pain & Epilepsy Applications: Highlighting real-world potential in Parkinson’s, facial pain, and more.
- CEO-Led Investor Meetings Emphasize Growth Trajectory: Ongoing innovation aimed at improved outcomes and reduced costs.
1. NeuroOne’s Vision: AI for Real-World Neurological Disorders
NeuroOne will join MedInvest’s MedTech, AI & Digital Health Conference in San Francisco on June 3–4, 2025, spotlighting its AI-integrated neurotech platforms. The company is applying artificial intelligence to enhance EEG recording, optimize surgical ablation, and advance stimulation therapies for conditions like epilepsy, Parkinson’s disease, dystonia, and essential tremor.
2. Expanding into High-Impact Clinical Applications
With a product roadmap that includes minimally invasive and high-definition devices, NeuroOne aims to reshape care for a growing population suffering from chronic neurological conditions. Potential future applications also include mood disorders, pain management, and AI-enhanced diagnostics for neurological mapping.
3. Industry Recognition and CEO-Led Conversations
President and CEO Dave Rosa will participate in high-level investor meetings and panels, positioning NeuroOne as a pivotal player in the AI-medical technology intersection. His leadership signals the company’s commitment to transparency, innovation, and rapid clinical adoption.
4. MedInvest: A Strategic Platform for Emerging Leaders
The MedInvest Conference brings together pioneering companies leveraging AI, digital health, and next-gen diagnostics. NeuroOne’s presence reinforces its strategic alignment with future-forward medtech investors and health system decision-makers.
By
